Zobrazeno 1 - 10
of 284
pro vyhledávání: '"Jaroslav, Cermak"'
Autor:
Jaroslav Cermak
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionInherited bone marrow failure (IBMF) syndromes are caused by mutations forming pathologic germline variants resulting in the production of defective hematopoietic stem cells (HSC) and in congenital failure in the production of one or more
Externí odkaz:
https://doaj.org/article/c1db6e8468114b0d9ea1a36e356682f4
Autor:
Iva Trsova, Andrea Hrustincova, Zdenek Krejcik, David Kundrat, Aleš Holoubek, Karolina Staflova, Lucie Janstova, Sarka Vanikova, Katarina Szikszai, Jiri Klema, Petr Rysavy, Monika Belickova, Monika Kaisrlikova, Jitka Vesela, Jaroslav Cermak, Anna Jonasova, Jiri Dostal, Jan Fric, Jan Musil, Michaela Dostalova Merkerova
Publikováno v:
Molecular Oncology, Vol 17, Iss 12, Pp 2565-2583 (2023)
Mutations in the splicing factor 3b subunit 1 (SF3B1) gene are frequent in myelodysplastic neoplasms (MDS). Because the splicing process is involved in the production of circular RNAs (circRNAs), we investigated the impact of SF3B1 mutations on circR
Externí odkaz:
https://doaj.org/article/cf124e1e1eda474f8d617a5629fc916b
Publikováno v:
Turkish Journal of Hematology, Vol 39, Iss 4, Pp 272-274 (2022)
Externí odkaz:
https://doaj.org/article/3086508766c34a8a891c49d10f4f111c
Autor:
Klara Pecankova, Pavla Pecherkova, Zdenka Gasova, Zofie Sovova, Tomas Riedel, Eliézer Jäger, Jaroslav Cermak, Pavel Majek
Publikováno v:
PLoS ONE, Vol 17, Iss 1 (2022)
Background Extracellular vesicles are released into body fluids from the majority of, if not all, cell types. Because their secretion and specific cargo (e.g., proteins) varies according to pathology, extracellular vesicles may prove a rich source of
Externí odkaz:
https://doaj.org/article/11b90946a2fa49f9a3b238428ed6da86
Autor:
Imre Bodó, Ismail Amine, Ana Boban, Horia Bumbea, Alexander Kulagin, Elena Lukina, Agnieszka Piekarska, Irena Preloznik Zupan, Juraj Sokol, Jerzy Windyga, Jaroslav Cermak
Publikováno v:
Advances in Therapy. 40:2752-2772
Autor:
Pedro da Silva-Coelho, Leonie I. Kroeze, Kenichi Yoshida, Theresia N. Koorenhof-Scheele, Ruth Knops, Louis T. van de Locht, Aniek O. de Graaf, Marion Massop, Sarah Sandmann, Martin Dugas, Marian J. Stevens-Kroef, Jaroslav Cermak, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Satoru Miyano, Theo de Witte, Nicole M. A. Blijlevens, Petra Muus, Gerwin Huls, Bert A. van der Reijden, Seishi Ogawa, Joop H. Jansen
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-11 (2017)
Myelodysplastic syndromes are a broad group of haematopoietic malignancies that often progress to acute myeloid leukaemia. Here, the authors show that linear and branched evolution occurs within myelodysplastic syndrome and these patterns can be impa
Externí odkaz:
https://doaj.org/article/15e723d7aa454140a35f949fbaeac555
Autor:
Michael Pfeilstocker, Heinz Tuechler, Lionel Ades, Jaroslav Cermak, Fatiha Chermat, Matteo G. Della Porta, Pierre Fenaux, Guillermo Garcia-Manero, Ulrich Germing, Detlef Haase, Andrea Kuendgen, Michael Luebbert, Silvia Maria Meira Magalhaes, Luca Malcovati, Yasushi Miyazaki, Guillermo Sanz, Valeria Santini, Mikkael A. Sekeres, Matthew J Walter, Peter Valent, Peter L Greenberg
Publikováno v:
Blood. 140:6976-6978
Autor:
Monika Kaisrlikova, Jitka Vesela, David Kundrat, Hana Votavova, Michaela Dostalova Merkerova, Zdenek Krejcik, Vladimir Divoky, Marek Jedlicka, Jan Fric, Jiri Klema, Dana Mikulenkova, Marketa Stastna Markova, Marie Lauermannova, Jolana Mertova, Jacqueline Soukupova Maaloufova, Anna Jonasova, Jaroslav Cermak, Monika Belickova
Publikováno v:
Leukemia. 36:1898-1906
Patients with lower-risk myelodysplastic syndromes (LR-MDS) have a generally favorable prognosis; however, a small proportion of cases progress rapidly. This study aimed to define molecular biomarkers predictive of LR-MDS progression and to uncover c
Autor:
Hana Votavova, Zuzana Urbanova, David Kundrat, Michaela Dostalova Merkerova, Martin Vostry, Monika Hruba, Jaroslav Cermak, Monika Belickova
Publikováno v:
Pharmaceuticals, Vol 14, Iss 1, p 41 (2021)
Deferasirox (DFX) is an oral iron chelator used to reduce iron overload (IO) caused by frequent blood cell transfusions in anemic myelodysplastic syndrome (MDS) patients. To study the molecular mechanisms by which DFX improves outcome in MDS, we anal
Externí odkaz:
https://doaj.org/article/4e59932ca0a745b3bfec0a888822a382
Autor:
Michaela Dostalova, Merkerova, Jiri, Klema, David, Kundrat, Katarina, Szikszai, Zdenek, Krejcik, Andrea, Hrustincova, Iva, Trsova, Anh Vu, LE, Jaroslav, Cermak, Anna, Jonasova, Monika, Belickova
Publikováno v:
Cancer Genomics Proteomics
Background/Aim: Prediction of response to azacitidine (AZA) treatment is an important challenge in hematooncology. In addition to protein coding genes (PCGs), AZA efficiency is influenced by various noncoding RNAs (ncRNAs), including long ncRNAs (lnc